|
Patients – n (%)
|
35 (56.4)
|
27 (43.6)
|
|
Duration (mo.) of PEGV therapy – median (range)
|
51 (15–72)
|
30 (6–72)*
|
|
Final weekly PEGV dose (mg) – median (range)
|
105 (70–210)
|
140 (70–280)
|
|
Final daily PEGV dose (mg)
| | |
|
10 mg – n (%)
|
10 (28.6)
|
11(40.7)
|
|
15 mg – n (%)
|
11 (31.4)
|
2 (7.4)
|
|
20 mg – n (%)
|
9 (25.7)
|
8 (29.6)
|
|
25 mg – n (%)
|
1 (2.8)
|
1 (3.7)
|
|
30 mg – n (%)
|
4 (11.4)
|
4 (14.8)
|
|
40 mg – n (%)
|
0 (0)
|
1 (3.7)
|
|
Group mean (±SD)
|
16.8 (±6.3)
|
17.9 (±8.4)
|
|
Group median (range)
|
15 (10–30)
|
20 (10–40)
|
|
Subgroup with IGF-I normalization at end of follow-up
|
15 (10–30)
|
10 (10–30)
|
|
Subgroup with abnormal IGF-I levels at end of follow-up
|
15 (10–20)
|
20 (10–40)*#
|
|
Pts. requiring dose reduction during follow-up
a
– n (%)
|
5 (14.3)
|
4 (14.8)
|
|
Pts. with IGF-I normalization at any time during follow-up
b
– n (%)
|
29 (82.8)
|
18 (66.7)
|
|
Pts. with IGF-I normalization at end of follow-up – n (%)
|
28 (80)
|
15 (55.5)*
|
|
Final IGF-I levels
| | |
|
μg/L,Median (range)
|
212 (110–1216)#
|
291 (150–1015)*#
|
|
SDS (range)
|
1.0 (−0.5–14.1)#
|
1.9 (−0.4–9.8)*#
|
|
μg/L,Mean (±SD)
|
269 (± 203)
|
372 (± 216)*#
|
|
Significant growth of (residual) adenoma - n (%)
|
0 (0)
|
1 (3.7)
|
|
Increase of liver enzymes - n (%)
|
5 (14.3)
|
3 (11.1)
|
|
Injections site events - n (%)
|
1 (2.9)
|
1 (3.7)
|
